Atazanavir: simplicity and convenience in different scenarios

Bibliography

• HAMMER S, SAAG M, SCHECHTER M et al.: Treatment for adult HIV infection 2006 recommendations of the International AIDS Society-USA panel. JAMA (2006) 296:827-843
   PubMed Web of Science ®Google Scholar
• BRISTOL-MEYERS SQUIBB CO.: REYATAZ® (atazanavir sulphate) capsules prescribing information. Bristol-Meyers Squibb Co., Princeton (NJ) USA (2006).
   Google Scholar
• ROBINSON BS, RICCARDI KA, GONG YF et al.: BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. Antimicrob. Agents Chemother. (2000) 44:2093-2099.
   PubMed Web of Science ®Google Scholar
• DRUSANO GL, BILELLO JA, PRESTON SL: Hollow-fiber evaluation of a new human immunodeficiency virus Type 1 protease inhibitor, BMS-232632, for determination of the linked pharmacodynamic variable. J. Infect. Dis. (2001) 183:1126-1129.
   PubMed Web of Science ®Google Scholar
• SANNE I, PILIERO P, SQUIRES K et al.: Results of a Phase II clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naïve subjects. J. Acquir. Immune Defic. Syndr. (2003) 32:18-29.
   PubMed Web of Science ®Google Scholar
• TABURET AM, PIKETTY C, CHAZALLON C et al.: Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. (2004) 48(6):2091-2096.
   PubMed Web of Science ®Google Scholar
• O’MARA E, AGARWALA S, RANDALL D, GERALDES M, STOLTZ R, MUMMANENI V: Steady-state pharmacokinetic interaction study of atazanavir (ATV) with efavirenz (EFV) in healthy subjects [abstract 444-W]. Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections. Seattle, WA, USA (24 – 28 February 2002).
   Google Scholar
• AGARWALA S, RUSSO R, MUMMANENI V, RANDALL D, GERALDES M, O’MARA E: Steady-state pharmacokinetic (PK) interaction study of atazanavir (ATV) with ritonavir (RTV) in healthy subjects [abstract H-1716]. Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA, USA (27 – 30 September 2002).
   Google Scholar
• MURPHY RL, SANNE I, CAHN P et al.: Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. AIDS (2003) 17:2603-2614.
   PubMed Web of Science ®Google Scholar
• SQUIRES K, LAZZARIN A, GATELL J et al.: Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J. Acquir. Immune Defic. Syndr. (2004) 36:1011-1019.
   PubMed Web of Science ®Google Scholar
• MALAN N, KRANTZ E, DAVID N et al.: Efficacy and safety of atazanavir-based therapy in antiretroviral naive HIV-1 infected subjects, both with and without ritonavir: 48-week results from AI424-089. Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO (5 – 8 February 2006) Abstr. 107LB.
   Google Scholar
• WOOD R, PHANUPHAK P, CAHN P et al.: Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir. J. Acquir. Immune Defic. Syndr. (2004) 36:684-692.
   PubMed Web of Science ®Google Scholar
• GATELL J, SALMON CERON D, LAZZARIN A et al.: Efficacy and safety of atazanavir (ATV) based HAART in patients switching from a stable boosted/unboosted protease inhibitor (PI) treatment: the SWAN study. Program and abstracts of the 10th European AIDS Conference. Dublin, Ireland (17 – 20 November 2005) Abstr. PS1/1.
   Google Scholar
• SWINDELLS S, DIRIENZO AG, WILKIN T et al.: Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression. JAMA (2006) 296(7):806-814.
   PubMed Web of Science ®Google Scholar
• HAAS D, ZALA C, SCHRADER S et al.: Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized comparative pilot trial. AIDS (2003) 17:1339-1349.
   PubMed Web of Science ®Google Scholar
• COHEN C, NIETO-CISNEROS L et al.; BMS AI424-043 STUDY GROUP: Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial. Curr. Med. Res. Opin. (2005) 21(10):1683-1692.
   PubMed Web of Science ®Google Scholar
• JOHNSON M, GRINSZTEJN B, RODRIGUEZ C et al.: 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS (2006) 20(5):711-718.
   PubMed Web of Science ®Google Scholar
• DRONDA F, ANTELA A, PEREZ-ELIAS MJ et al.: Rescue therapy with once-daily atazanavir-based regimens for antiretroviral-experienced HIV-infected patients. J. Acquir. Immune Defic. Syndr. (2006) 42(2):258-259.
   PubMedGoogle Scholar
• PIKETTY C, GERARD L, CHAZALLON C: Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trial. Antivir. Ther. (2006) 11(2):213-221.
   PubMedGoogle Scholar
• PEREZ-ELÍAS MJ, GATELL J, FLORES J et al.: Effect of ritonavir-boosted atazanavir (ATV/r) in experienced HIV-infected patients regarding hepatitis B/C status. 3rd IAS Conference on HIV Pathogenesis and Treatment. Rio de Janeiro, Brazil (24 – 27 July 2005) Abstr. TuPe1.1C25.
   Google Scholar
• PINEDA JA, PALACIOS R, RIVERO A et al.: Low incidence of severe liver toxicity in patients receiving antiretroviral combinations including atazanavir. J. Antimicrob. Chemother. (2006) 57(5):1016-1017.
   PubMed Web of Science ®Google Scholar
• WITEK J, MC CALLISTER S, ODESHOO L et al.: Safety of atazanavir (ATV) and atazanavir/ritonavir (ATV/r) in subjects co-infected with HIV and hepatitis B and/or C: 1100 subject-years of treatment exposure. AIDS 2006 XVI International AIDS Conference. Toronto, Canada (13 – 18 August 2006) Abstr. WEPE0054.
   Google Scholar
• MORRIS A, JUETHNER S, THEROUX E: Atazanavir use in pregnancy. 3rd IAS Conference on HIV Pathogenesis and Treatment. Rio de Janeiro, Brazil (24 – 27 July 2005) Abstr. TuPe5.2P01.
   Google Scholar
• O’MARA E, MUMMANENI V, RANDALL D et al.: Assessment of the effect of uridine diphosphate glucuronosyl transferase 1A1 genotype on indirect bilirubin elevations in healthy subjects dosed with BMS-232632. Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada (17 – 20 September 2000). Abstr. 1645.
   Google Scholar
• PERSICO M, PERSICO E, BAKKER CT et al.: Hepatic uptake of organic anions affects the plasma bilirubin level in subjects with Gilbert’s syndrome mutations in UGT1A1. Hepatology (2001) 33:627-632.
   PubMedGoogle Scholar
• ROTGER M, TAFFE P, BLEIBER G et al.: Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. J. Infect. Dis. (2005) 192:1381-1386.
   PubMed Web of Science ®Google Scholar
• LANKISCH TO, MOEBIUS U, WEHMEIER M et al.: Gilbert’s disease and atazanavir: from phenotype to UDP-glucuronosyl transferase haplotype. Hepatology (2006) 44(5):1324-1332.
   PubMed Web of Science ®Google Scholar
• RODRIGUEZ NOVOA S, BARREIRO P, RENDON A et al.: Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C > T polymorphism at the multidrug resistance gene 1. Clin. Infect. Dis. (2006) 42(2):291-295.
   PubMed Web of Science ®Google Scholar
• SMITH K, WEINBERG W, DEJESUS E et al.: Efficacy and safety of once-daily boosted fosamprenavir (FPV/r) or atazanavir (ATV/r) with tenofovir (TDF)/emtricitabine (FTC) in antiretroviral-naive HIV-infected patients: 24-week results from COL103952 (ALERT). Program and abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA (27 – 30 September 2006) Abstr. H-1670a.
   Google Scholar
• JEMSEK J, ARATHOON E, ARLOTTI M et al.: Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naïve HIV-infected patients. Clin. Infect. Dis. (2006) 42:273-280.
   PubMed Web of Science ®Google Scholar
• NOOR M, PARKER R, O’MARA E: The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults. AIDS (2004) 18:2137-2144.
   PubMed Web of Science ®Google Scholar
• PRESTON S, PILIERO P, O’MARA E et al.: Evaluation of the steady-state interaction between atazanavir (ATV) and efavirenz (EFV). Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections. Seattle, WA, USA (24 – 28 February 2002) Abstr. 443.
   Google Scholar
• DAILLY E, TRIBUT O, TATTEVIN P et al.: Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients. Eur. J. Clin. Pharmacol. (2006) 62(7):523-526.
   PubMed Web of Science ®Google Scholar
• O’MARA E, MUMMANENI V, BIFANO M et al.: Pilot study of the interaction between BMS-232632 and ritonavir. 8th Conference on Retroviruses and Opportunistic Infections. Chicago, IL, USA (4 – 8 February 2002) Abstr. 740.
   Google Scholar
• BOFFITO M, KUROWSKI M, KRUSE G et al.: Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir- boosted once-daily regimen. AIDS (2004) 18:1291-1297.
   PubMed Web of Science ®Google Scholar
• GUFFANTI M, DE PASCALIS C, SEMINARI E et al.: Pharmacokinetics of amprenavir given once or twice a day when combined with atazanavir in heavily pre-treated HIV-positive patients. AIDS (2003) 17:2669-2672.
   PubMed Web of Science ®Google Scholar
• KISER JJ, LICHTENSTEIN KA, ANDERSON PL, FLETCHER CV: Effects of esomeprazole on the pharmacokinetics of atazanavir and fosamprenavir in a patient with human immunodeficiency virus infection. Pharmacotherapy (2006) 26(4):511-514.
   PubMed Web of Science ®Google Scholar
• TOMILO DL, SMITH PF, OGUNDELE AB et al.: Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteers. Pharmacotherapy (2006) 26(3):341-346.
   PubMed Web of Science ®Google Scholar
• GUIARD-SCHMID JB, POIRIER JM, BONNARD P, MEYNARD JL: Lack of interaction between atazanavir and proton pump inhibitors in HIV-infected patients treated with ritonavir-boosted atazanavir. J. Acquir. Immune Defic. Syndr. (2005) 39(4):503.
   Google Scholar
• MUMMANENI V, RANDALL D, CHABUEL D, GERALDES M, O’MARA E: Steady-state pharmacokinetic (PK) interaction study of atazanavir (ATV) with clarithromycin (CLR) in healthy subjects. Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA, USA (27 – 30 September 2002). Abstr. H-1717.
   Google Scholar
• FRIEDLAND G, ANDREWS L, SCHREIBMAN T et al.: Lack of an effect of atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction. AIDS (2005) 19(15):1635-1641.
   PubMed Web of Science ®Google Scholar
• GONG YF, ROBINSON BS, ROSE RE et al.: In vitro resistance profile of the human immunodeficiency virus Type 1 protease inhibitor BMS-232632. Antimicrob. Agents Chemother. (2000) 44:2319-2326.
   PubMed Web of Science ®Google Scholar
• COLONNO R, ROSE R, MCLAREN C et al.: Identification of I50L as the signature atazanavir resistance mutation in treatment naïve HIV-1 patients receiving atazanavir-containing regimens. J. Infect. Dis. (2004) 189:1802-1810.
   PubMed Web of Science ®Google Scholar
• YANCHUNAS J JR, LANGLEY DR, TAO L: Molecular basis for increased susceptibility of isolates with atazanavir resistance-conferring substitution I50L to other protease inhibitors. Antimicrob. Agents Chemother. (2005) 49(9):3825-3832.
   PubMed Web of Science ®Google Scholar
• WEINHEIMER S, DISCOTTO L, FRIBORG J, YANG H, COLONNO R: Atazanavir signature I50L resistance substitution accounts for unique phenotype of increased susceptibility to other protease inhibitors in a variety of human immunodeficiency virus Type 1 genetic backbones. Antimicrob. Agents Chemother. (2005) 49(9):3816-3824.
   PubMed Web of Science ®Google Scholar
• SCHNELL T, SCHMIDT B, MOSCHIK G et al.: Distinct cross-resistance profiles of the new protease inhibitors amprenavir, lopinavir, and atazanavir in a panel of clinical samples. AIDS (2003) 17:1258-1261.
   PubMed Web of Science ®Google Scholar
• COLONNO RJ, THIRY A, LIMOLI K, PARKIN N: Activities of atazanavir (BMS-232632) against a large panel of human immunodeficiency virus Type 1 clinical isolates resistant to one or more approved protease inhibitors. Antimicrob. Agents Chemother. (2003) 47:1324-1333.
   PubMed Web of Science ®Google Scholar
• PELLEGRIN I, BREILH D, RAGNAUD JM et al.: Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study). Antivir Ther. (2006) 11(4):421-429.
   PubMed Web of Science ®Google Scholar
• NAEGER LK, STRUBLE KA: Effect of baseline protease genotype and phenotype on HIV response to atazanavir/ritonavir in treatment-experienced patients. AIDS (2006) 20(6):847-853.
   PubMed Web of Science ®Google Scholar
• VORA S, MARCELIN AG, GUNTHARD HF et al.: Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitor-experienced patients. AIDS (2006) 20(1):35-40.
   PubMed Web of Science ®Google Scholar
• COAKLEY E, CHAPPEY C, MAA J et al.: Evaluation of phenotypic clinical cutoff for atazanavir/ritonavir in patients who changed only the protease inhibitor component of HAART: a confirmatory week 2 analysis of AI424-045. Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections Denver, CO (5 – 8 February 2006) Abstr. 634.
   Google Scholar
• RAY JE, MARRIOTT D, BLOCH MT, MCLACHLAN AJ et al.: Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic. Br. J. Clin. Pharmacol. (2005) 60(3):291-299.
   PubMed Web of Science ®Google Scholar
• BARRIOS A, RENDON AL, GALLEGO O et al.: Predictors of virological response to atazanavir in protease inhibitor-experienced patients. HIV Clin. Trials. (2004) 5(4):201-205.
   PubMed Web of Science ®Google Scholar
• GIANOTTI N, SEMINARI E, GUFFANTI M et al.: Evaluation of atazanavir Ctrough, atazanavir genotypic inhibitory quotient, and baseline HIV genotype as predictors of a 24-week virological response in highly drug-experienced, HIV-infected patients treated with unboosted atazanavir. New Microbiol. (2005) 28(2):119-125.
   PubMedGoogle Scholar
• RICHTER A, PLADEVALL M, MANJUNATH R et al.: Patient characteristics and costs associated with dyslipidaemia and related conditions in HIV-infected patients: a retrospective cohort study. HIV Med. (2005) 6(2):79-90.
   PubMed Web of Science ®Google Scholar